Overview

Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
evaluate the safety and tolerability of ITCA 650 in subjects with type 2 diabetes mellitus.
Phase:
Phase 1
Details
Lead Sponsor:
Intarcia Therapeutics
Treatments:
Exenatide